Successful treatment with MEK‐inhibitor in a patient with NRAS‐related cutaneous skeletal hypophosphatemia syndrome

D Carli, S Cardaropoli, D Tessaris… - Genes …, 2022 - Wiley Online Library
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is caused by somatic mosaic
NRAS variants and characterized by melanocytic/sebaceous naevi, eye, and brain …
被引用次数：9 相关文章

Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome.

D Carli, S Cardaropoli, D Tessaris, P Coppo… - Genes …, 2022 - europepmc.org
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is caused by somatic mosaic
NRAS variants and characterized by melanocytic/sebaceous naevi, eye, and brain …
[HTML] nih.gov

[HTML][HTML] Successful treatment with MEK‐inhibitor in a patient with NRAS‐related cutaneous skeletal hypophosphatemia syndrome

D Carli, S Cardaropoli, D Tessaris… - Genes …, 2022 - ncbi.nlm.nih.gov
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is caused by somatic mosaic
NRAS variants and characterized by melanocytic/sebaceous naevi, eye, and brain …

Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome

D Carli, S Cardaropoli, D Tessaris, P Coppo… - GENES …, 2022 - iris.unito.it
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is caused by somatic mosaic
NRAS variants and characterized by melanocytic/sebaceous naevi, eye, and brain …
[PDF] academia.edu

[PDF][PDF] Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome

D Carli, S Cardaropoli, D Tessaris, P Coppo… - 2022 - academia.edu
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is caused by somatic mosaic
NRAS variants and characterized by melanocytic/sebaceous naevi, eye, and brain …

Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome

D Carli, S Cardaropoli, D Tessaris… - Genes …, 2022 - pubmed.ncbi.nlm.nih.gov
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is caused by somatic mosaic
NRAS variants and characterized by melanocytic/sebaceous naevi, eye, and brain …
[PDF] unito.it

[PDF][PDF] Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome

D Carli, S Cardaropoli, D Tessaris, P Coppo… - 2022 - iris.unito.it
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is caused by somatic mosaic
NRAS variants and characterized by melanocytic/sebaceous naevi, eye, and brain …